Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Pharmaceutical firm Vertex Pharmaceuticals provided an undisclosed amount of equity funding for US-based immunotherapy developer Kymera Therapeutics on Wednesday as part of a $70m upfront payment made as part of a research and development agreement. Kymera had previously raised $95m across two rounds, from investors including corporate venturing units Lilly Ventures, Amgen Ventures, Pfizer Ventures, MRL Ventures Fund and Sanofi Ventures, as of November 2018.
NestAway, an India-based online accommodation portal that counts e-commerce company Flipkart among its investors,…
